WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326874

CAS#: 27470-51-5

Description: Suxibuzone is a analgesic used for joint and muscular pain. It is a prodrug of the non-steroidal anti-inflammatory drug phenylbutazone, and is commonly used in horses.

Chemical Structure

CAS# 27470-51-5

Theoretical Analysis

MedKoo Cat#: 326874
Name: Suxibuzone
CAS#: 27470-51-5
Chemical Formula: C24H26N2O6
Exact Mass: 438.1791
Molecular Weight: 438.48
Elemental Analysis: C, 65.74; H, 5.98; N, 6.39; O, 21.89

Price and Availability

Size Price Availability Quantity
100.0mg USD 250.0 2 Weeks
500.0mg USD 600.0 2 Weeks
5.0g USD 4500.0 2 Weeks
Bulk inquiry

Synonym: AE-17; AE17; AE 17; Suxibuzone; Flamilon; Flogos; Solurol.

IUPAC/Chemical Name: 4-((4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy)-4-oxobutanoic acid


InChi Code: InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 438.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Andrews FM, Reinemeyer CR, Longhofer SL. Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses. Vet Ther. 2009 Fall;10(3):113-20. PubMed PMID: 20037965.

2: Sabaté D, Homedes J, Salichs M, Sust M, Monreal L. Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses. Equine Vet J. 2009 Sep;41(7):700-5. PubMed PMID: 19927590.

3: Monreal L, Sabaté D, Segura D, Mayós I, Homedes J. Lower gastric ulcerogenic effect of suxibuzone compared to phenylbutazone when administered orally to horses. Res Vet Sci. 2004 Apr;76(2):145-9. PubMed PMID: 14672858.

4: Jaraiz MV, Rodriguez C, San Andres MD, Gonzalez F, San Andres MI. Disposition and tolerance of suxibuzone in horses. Equine Vet J. 1999 Sep;31(5):411-6. PubMed PMID: 10505957.

5: Jaraiz V, Rodriguez C, San Andres MD, Gonzalez F, San Andres MI. Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. J Vet Pharmacol Ther. 1999 Aug;22(4):247-54. PubMed PMID: 10499236.

6: Delbeke FT, Vynckier L, Debackere M. The disposition of suxibuzone in the horse. J Vet Pharmacol Ther. 1993 Sep;16(3):283-90. PubMed PMID: 8230399.

7: Caturla MC, Cusido E. Solid-phase extraction for the high-performance liquid chromatographic determination of indomethacin, suxibuzone, phenylbutazone and oxyphenbutazone in plasma, avoiding degradation of compounds. J Chromatogr. 1992 Oct 2;581(1):101-7. PubMed PMID: 1429991.

8: Yanagi S, Sakamoto M, Takahashi S, Tsutsumi M, Konishi Y, Shibata K, Kamiya T. Promotion of hepatocarcinogenesis by suxibuzone in rats initiated with 3'-methyl-4-dimethylaminoazobenzene. Cancer Lett. 1987 Jul;36(1):11-8. PubMed PMID: 3107799.

9: Mizushima Y, Shiokawa Y, Honma M, Kageyama T. A double-blind comparison of phenylbutazone and suxibuzone, a prodrug of phenylbutazone, in rheumatoid arthritis. Int J Tissue React. 1983;5(1):35-9. PubMed PMID: 6345427.

10: Yasuda Y, Shindo T, Mitani N, Ishida N, Oono F, Kageyama T. Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans. J Pharm Sci. 1982 May;71(5):565-72. PubMed PMID: 7097505.

11: Marunaka T, Shibata T, Minami Y, Umeno Y, Shindo T. Simultaneous high-performance liquid chromatographic determination of suxibuzone and its metabolites in plasma and urine. J Pharm Sci. 1980 Nov;69(11):1258-61. PubMed PMID: 7452452.

12: Taira K, Yasuda Y, Shindo T, Mitani N, Akazawa A. [The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione (suxibuzone), antiinflammatory drug. II. The biological fate of suxibuzone (SB) after daily oral administration (author's transl)]. Yakugaku Zasshi. 1980 Mar;100(3):272-9. Japanese. PubMed PMID: 7381687.

13: Shindo T, Yasuda Y, Taira K, Mitani N, Kanda A, Akazawa A. [The biological fate of 4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione(sux ibuzone), antiinflammatory drug. I. Plasma levels and urinary excretion after oral administration of suxibuzone (author's transl)]. Yakugaku Zasshi. 1979 Dec;99(12):1186-200. Japanese. PubMed PMID: 120893.

14: Sariols Gómez M. [Clinical efficiency of the anti-inflammatory anesthetic combination suxibuzone-N.A.P.A]. Rev Esp Reum Enferm Osteoartic. 1976;19(3):305-12. Spanish. PubMed PMID: 792973.

15: Erill S, Laporte J. Uricosuric activity of suxibuzone, a new phenylbutazone derivative. Arch Farmacol Toxicol. 1975 Mar;1(1):43-6. PubMed PMID: 1231648.


100.0mg / USD 250.0